References | |
1. | Goette A, et al. Edoxaban-based versus vitamin-K-antagonist-based anti-thrombotic regimen following successful coronary stenting in atrial fibrillation patients. The ENTRUST-AF PCI trial. Presented at: ESC Congress 2019; September 03, 2019; Paris. |
2. | Vranckx P, et al. Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial. Lancet, in press |
3. | Capodanno D, Huber K, Mehran R, et al. Management of antithrombotic therapy in atrial fibrillation patients undergoing PCI: JACC State-of-the-Art Review. J Am Coll Cardiol 2019; 74(1): 83-99. |
4. | European Heart Journal, Volume 39, Issue 16, 21 April 2018, Pages 1330–1393, https://doi.org/10.1093/eurheartj/ehy136 |
5. | National Heart, Lung and Blood Institute – What is atrial fibrillation. Available at: http://www.nhlbi.nih.gov/health/dci/Diseases/af/af_diagnosis.html. [Last accessed: July 2019]. |
6. | Canvector, https://canet-nce.ca/our-work/research/atrial-fibrilation/, Consulted August 29, 2019. |
7. | Iqbal MB, et al. Recent developments in atrial fibrillation. BMJ. 2005;330(7485):238–43. |
8. | Camm A, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010;31(19):2369-2429. |
9. | Ball J, et al. Atrial fibrillation: Profile and burden of an evolving epidemic in the 21st century. Int J Card. 2013;167:1807-1824. |
